Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma

European Journal of Cancer Part A

Volumn 33, Issue 8, 1997, Pages 1323-1325

  Aviles A ^a   Diaz Maqueo J C ^a   Talavera, A ^a   Garcia E L ^a   Guzman R ^a   Nambo, M J ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Amifostine; Chemotherapy; Cyclophosphamide; Granulocytopenia; Malignant lymphoma; Non Hodgkin's lymphoma

Indexed keywords

AMIFOSTINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGRANULOCYTOSIS; AMIFOSTINE; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

EID: 0030789852     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00127-5     Document Type: Article

References (9)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328, 1124-1129.
2. Avilés A, Guzmán R, Delgado S, Nambo MJ, García EL, Díaz-Maqueo JC. Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis of aggressive malignant lymphoma. Am J Hematol 1996, 52, 275-280.
3. McCulloch W, Scheffer BJ, Schein PJ. New protective agents for bone marrow cancer therapy. Cancer Invest 1991, 9, 279-287.
4. Gentile P, Epremian BE. Approaches to ablating the myelotoxicity of chemotherapy. Crit Rev Hematol Oncol 1987, 7, 71-81.
5. Spencer CM, Goa KL. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as an radioprotector and cytotoxic chemoprotector. Drugs 1995, 50, 1001-1031.
6. Capizzi RL, Oster W. Protection of normal tissue from cytotoxic effects of chemotherapy and radiation by amifostine. Clinical experiences. Eur J Cancer 1995, 31A(Suppl. 1), 8-13.
7. Douay HC, Giarnatana C, Gorin NC. Amifostine (WR-2721) protects normal hematopoietic stem cells against cyclophosphamide derivatives toxicity without compromising their antileukemic effects. Eur J Cancer 1995, 31A(Suppl. 1), 14-16.
8. Schiller JH, Stone B, Berlin J, et al. Amifostine, cisplatin and vinblastine in metastatic non-small cell lung cancer. A report of high response rates and prolonged survival. J Clin Oncol 1996, 14, 1913-1921.
9. The International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329, 987-996.